^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT151

    i
    Other names: BNT151
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    1m
    BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=84, Active, not recruiting, BioNTech SE | Trial completion date: Jun 2026 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BNT151
    5ms
    BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=84, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    BNT151
    3years
    [VIRTUAL] An RNA-encoded IL-2 variant with an extended half-life mediates synergistic anti-tumor activity when combined with immune checkpoint blockade (CIMT 2021)
    Tumor control of the combination treatment was accompanied by increased numbers of neoantigen-specific T cells and a T cell phenotype previously associated with successful cancer immunotherapy. An open-label, Phase I/II, first-in-human trial in patients with advanced solid tumors was recently initiated to further explore the clinical safety and efficacy of BNT151 as monotherapy or in combination with other anti-cancer agents (NCT04455620).
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    IL2-L
    |
    BNT151